KTRA TD202sh 80%down

 10:07a ET 8/3/2022 - Benzinga

Why Kintara Therapeutics Stock Is Skyrocketing Today

Mentioned:

KTRA

Kintara Therapeutics Inc (NASDAQ: KTRA) shares are trading higher by 76.8% to $0.31 Wednesday morning after the company entered into an equity purchase agreement with Lincoln Park Capital for up to $20 million.

What Happened?

Kintara Therapeutics says the company expects this commitment from LPC will provide financial flexibility and is aligned with Kintara's long-term strategy for value creation.

Kintara intends to use any net proceeds from the sale of its common stock to LPC for working capital and general corporate purposes, including development expenses for VAL-083 and REM-001.

Why it Matters

"We are excited to enter into this transaction with Lincoln Park Capital and believe that this agreement provides us an opportunity to access capital in a very efficient manner," said Robert E. Hoffman, President and Chief Executive Officer of Kintara.

"We believe that the financial flexibility provided by this agreement will further support our clinical development efforts with VAL-083 in glioblastoma and REM-001 in cutaneous metastatic breast cancer."

See Also: Ping Identity Stock Is Skyrocketing: What's Happening?

According to data from Benzinga Pro, Kintara Therapeutics has a 52-week high of $1.65 and a 52-week low of $0.14.

© 2022 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

Mullen

 About Mullen

Mullen is a Southern California-based automotive company that owns and partners with several synergistic businesses working toward the unified goal of creating clean and scalable energy solutions. Mullen has evolved over the past decade in sync with consumers and technology trends. Today, the Company is working diligently to provide exciting EV options built entirely in the United States and made to fit perfectly into the American consumer’s life. Mullen strives to make EVs more accessible than ever by building an end-to-end ecosystem that takes care of all aspects of EV ownership.

Forward-Looking Statements
Certain statements in this press release that are not historical facts are forward-looking statements within the meaning of Section 27A of the Securities Exchange Act of 1934, as amended. Any statements contained in this press release that are not statements of historical fact may be deemed forward-looking statements. Words such as "continue," "will," "may," "could," "should," "expect," "expected," "plans," "intend," "anticipate," "believe," "estimate," "predict," "potential" and similar expressions are intended to identify such forward-looking statements. All forward-looking statements involve significant risks and uncertainties that could cause actual results to differ materially from those expressed or implied in the forward-looking statements, many of which are generally outside the control of Mullen and are difficult to predict. Examples of such risks and uncertainties include but are not limited to whether the Company will achieve its objectives of launching its EV crossover, the FIVE, within anticipated timelines and, if so, if the FIVE will be a success; whether production of  its own EV battery packs will be successful, reduce dependency on third-party suppliers or result in lower costs and increased overall quality; and whether the Company’s partnerships with ARRK, Dürr, and DSA Systems and Over the Air (OTA) will result in expediting the rollout of the FIVE. Additional examples of such risks and uncertainties include, but are not limited to: (i) Mullen’s ability (or inability) to obtain additional financing in sufficient amounts or on acceptable terms when needed; (ii) Mullen's ability to maintain existing, and secure additional, contracts with manufacturers, parts and other service providers relating to its business; (iii) Mullen’s ability to successfully expand in existing markets and enter new markets; (iv) Mullen’s ability to successfully manage and integrate any acquisitions of businesses, solutions or technologies; (v) unanticipated operating costs, transaction costs and actual or contingent liabilities; (vi) the ability to attract and retain qualified employees and key personnel; (vii) adverse effects of increased competition on Mullen’s business; (viii) changes in government licensing and regulation that may adversely affect Mullen’s business; (ix) the risk that changes in consumer behavior could adversely affect Mullen’s business; (x) Mullen’s ability to protect its intellectual property; and (xi) local, industry and general business and economic conditions. Additional factors that could cause actual results to differ materially from those expressed or implied in the forward-looking statements can be found in the most recent annual report on Form 10-K, quarterly reports on Form 10-Q and current reports on Form 8-K filed by Mullen with the Securities and Exchange Commission. Mullen anticipates that subsequent events and developments may cause its plans, intentions and expectations to change. Mullen assumes no obligation, and it specifically disclaims any intention or obligation, to update any forward-looking statements, whether as a result of new information, future events or otherwise, except as expressly required by law. Forward-looking statements speak only as of the date they are made and should not be relied upon as representing Mullen’s plans and expectations as of any subsequent date.

ALNA news 7/19/2022

 8:01a ET 7/19/2022 - Benzinga

Allena Pharmaceuticals Announces Completion Of Enrollment Of Cohorts A And B Of ALLN-346 Phase 2a Study 202 In Patients With Gout And Stages 2 And 3 Chronic Kidney Disease

Mentioned:

ALNA

Allena Pharmaceuticals, Inc. (NASDAQ:ALNA) ("Allena" or the "Company"), a biopharmaceutical company deploying its novel oral biologic platform to discover, develop and commercialize first-in-class, oral enzyme therapeutics for difficult-to treat metabolic diseases, today reported completion of enrollment of the first two cohorts of its ALLN-346 Phase 2a Study 202 in gout patients with stage 2 (cohort A) and stage 3 (cohort B) chronic kidney disease (CKD). ALLN-346, which has received Fast Track Designation from the U.S. Food and Drug Administration (FDA), is a first-in-class, non-absorbed, orally administered enzyme in development for the treatment of hyperuricemia and gout in the setting of advanced CKD, an indication with high unmet need. ALLN-346 is a bio-engineered enzyme specifically designed to degrade urate in the gastrointestinal tract without systemic absorption and thereby reduce systemic urate levels in patients with hyperuricemia, gout and CKD. 

Study 202 is a two-week, outpatient study assessing safety and tolerability in hyperuricemic patients with gout and CKD. Patients are randomized (2:1) to receive either five capsules of ALLN-346 or a matching placebo three times daily, with enrollment of up to four planned cohorts, each consisting of up to 12 patients. Cohort A has enrolled seven patients with an estimated glomerular filtration rate (eGFR) of 60-89 mL/minute (considered to have Stage 2, or mild CKD), and Cohort B has enrolled twelve patients with an eGFR of 30-59 mL/minute (considered to have Stage 3, or moderate CKD). Of note, because Study 201, a one-week inpatient study conducted at a clinical pharmacology unit, has enrolled primarily hyperuricemic patients with Stage 2 CKD, targeted enrollment of Stage 2 CKD patients in Cohort A of Study 202 was reduced from twelve to seven. Topline safety and efficacy data from cohort A and cohort B of Study 202 are expected to be available later this quarter. Pending review of the Phase 2a data and the availability of sufficient financial resources, the Company expects to open two additional cohorts later this year, consisting of gout patients with Stage 4, or advanced CKD (Cohort C) and an allopurinol combination therapy cohort in gout patients with Stage 3 CKD (Cohort D).

© 2022 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

ALNA up today 8/4/2022 3:30am

8/3/2022 closed 0.12$

 

XELA 4-8pm 3 August 2022

 

Continues to Sign New Logos for XBP(R) Mentioned: XELA

 7:30a ET 8/3/2022 - Globe Newswire

Exela Continues to Sign New Logos for XBP(R)

Mentioned:

XELA

EQNX::TICKER_START (NASDAQ:XELA),(OTC US:XELAW),(Other OTC:XELAW),(NASDAQ:XELAP), EQNX::TICKER_END Exela Technologies, Inc. ("Exela") (NASDAQ: XELA, XELAP), today announced a new contract with a large European domiciled financial services firm that will utilize Exela's Exchange for Bills and Payments ("XBP"), the largest revenue contributor of the $874.2 million ITPS accounting segment for FY 2021. The total contract value ("TCV") over the 5-year term is valued at approximately $6 million.

Exela is a leader in bills and payment processing with more than thirty years of experience handling complex problems and delivering simplicity. XBP liquidity solutions allow billers, consumers and businesses to communicate and transact. Offering a complete solution to its customers, Exela enables improved control, insights and analytics globally in over 50 countries. The customer will deploy Exela's Digital Mail Room (DMR) module as part of our XBP Global platform to process payments, account opening requests and other critical banking documents.

"Exela's XBP Global platform continues to resonate in the market and we are pleased to add another prominent new logo. The convenience, security and flexibility of XBP Global offer an accelerated digital transformation journey for customers across all verticals we serve," said Vitalie Robu, President of Exela, EMEA.

About Exela Technologies

Exela Technologies is a business process automation (BPA) leader, leveraging a global footprint and proprietary technology to provide digital transformation solutions enhancing quality, productivity, and end-user experience. With decades of experience operating mission-critical processes, Exela serves a growing roster of more than 4,000 customers throughout 50 countries, including over 60% of the Fortune 100. Utilizing foundational technologies spanning information management, workflow automation, and integrated communications, Exela's software and services include multi-industry, departmental solution suites addressing finance and accounting, human capital management, and legal management, as well as industry-specific solutions for banking, healthcare, insurance, and the public sector. Through cloud-enabled platforms, built on a configurable stack of automation modules, and approximately 17,000 employees operating in 23 countries, Exela rapidly deploys integrated technology and operations as an end-to-end digital journey partner.

For more Exela news, commentary, and industry perspectives, visit: https://investors.exelatech.com/

And please follow us on social:

Twitter: https://twitter.com/exelatech

LinkedIn: https://www.linkedin.com/company/exela-technologies

Facebook: https://www.facebook.com/exelatechnologies/

Instagram: https://www.instagram.com/exelatechnologies

The information posted on the Company's website and/or via its social media accounts may be deemed material to investors. Accordingly, investors, media and others interested in the Company should monitor the Company's website and its social media accounts in addition to the Company's press releases, SEC filings and public conference calls and webcasts.

Forward-Looking Statements

Certain statements included in this press release are not historical facts but are forward-looking statements for purposes of the safe harbor provisions under The Private Securities Litigation Reform Act of 1995. Forward-looking statements generally are accompanied by words such as "may", "should", "would", "plan", "intend", "anticipate", "believe", "estimate", "predict", "potential", "seem", "seek", "continue", "future", "will", "expect", "outlook" or other similar words, phrases or expressions. These forward-looking statements include statements regarding our industry, future events, estimated or anticipated future results and benefits, future opportunities for Exela, and other statements that are not historical facts. These statements are based on the current expectations of Exela management and are not predictions of actual performance. These statements are subject to a number of risks and uncertainties, including without limitation those discussed under the heading "Risk Factors" in Exela's Annual Report and other securities filings. In addition, forward-looking statements provide Exela's expectations, plans or forecasts of future events and views as of the date of this communication. Exela anticipates that subsequent events and developments will cause Exela's assessments to change. These forward-looking statements should not be relied upon as representing Exela's assessments as of any date subsequent to the date of this press release.

Investor and/or Media Contacts:

Vincent Kondaveeti

E: vincent.kondaveeti@exelatech.com

Mary Beth Benjamin

E: IR@exelatech.com

https://ml.globenewswire.com/media/156e5f7b-cc2b-47c9-98da-10587830d29c/small/exela-826x374-png.png

https://ml.globenewswire.com/media/156e5f7b-cc2b-47c9-98da-10587830d29c/small/exela-826x374-png.png

COMTEX_411493292/2010/2022-08-03T07:30:06